Many women with epilepsy experience perimenstrual seizure exacerbation, referred to as catamenial epilepsy. There is no effective treatment for this condition, proposed to result from withdrawal of neurosteroid-mediated effects of progesterone. A double-blind, multicenter, phase III, clinical trial of catamenial epilepsy has failed to find a beneficial effect of progesterone. The neurosteroid-mediated effects of progesterone have been extensively studied in relation to catamenial epilepsy; however, the effects mediated by progesterone receptor activation have been overlooked. We determined whether progesterone increased excitatory transmission in the hippocampus via activation of progesterone receptors, which may play a role in regulating catamenial seizure exacerbation. In a double-blind study using a rat model of catamenial epilepsy, we found that treatment with RU-486, which blocks progesterone and glucocorticoid receptors, significantly attenuated neurosteroid withdrawalinduced seizures. Furthermore, progesterone treatment as well as endogenous rise in progesterone during estrous cycle increased the expression of GluA1 and GluA2 subunits of AMPA receptors in the hippocampi, and enhanced the AMPA receptor-mediated synaptic transmission of CA1 pyramidal neurons. The progesterone-induced plasticity of AMPA receptors was blocked by RU-486 treatment and progesterone also failed to increase AMPA receptor expression in progesterone receptor knockout mice. These studies demonstrate that progesterone receptor activation regulates AMPA receptor expression and may play a role in catamenial seizure exacerbation.
Introduction
Approximately 30% of women of reproductive age with epilepsy experience cyclical exacerbation of seizures related to periodic changes in the serum progesterone and estrogen levels during the menstrual cycle (catamenial epilepsy) and its predominant form is perimenstrual seizure exacerbation (Herzog et al., 2015; Frye, 2008) . Currently there are no scientifically-tested effective treatments of catamenial exacerbation. This period of seizure exacerbation coincides with a decline in progesterone levels at the end of the cycle following the mid-luteal peak levels.
Progesterone is a sedative and exerts an anticonvulsant action via conversion to the neurosteroid allopregnanolone, which binds to γ-amino-butyric acid (GABA) type A (GABA A ) receptors, and enhances GABA action on the receptor (Reddy and Rogawski, 2012; Joshi et al., 2013) . It has long been proposed that perimenstrual seizure exacerbation is related to neurosteroid withdrawal, which would impair GABAergic inhibition. Based on the premise that maintaining high progesterone and allopregnanolone levels during the perimenstrual period would alleviate seizure exacerbation, a large-scale phase 3 clinical trial was conducted. However, in this trial, progesterone replacement therapy was not different than placebo to protect against this exacerbation (Herzog, 2015) .
Progesterone also activates the progesterone receptors, isoforms A and B, which are ligand-activated transcription factors encoded by a single gene (Conneely et al., 1987) . Upon activation, progesterone receptors localize to the nucleus and regulate gene expression (Mani and Oyola, 2012; Singh and Su, 2013) . The mRNA and protein of progesterone receptors are present in the principal neurons of the hippocampus, which is involved in seizure generation and propagation (Guerra-Araiza et al., 2003; Guerra-Araiza et al., 2000) . The immunoreactivity of progesterone receptors is present over the soma, axon terminals, and dendritic spines of hippocampal principal neurons (Mitterling et al., 2010) . While the allopregnanolone-mediated effects
